Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemoradiotherapy plus brachytherapy for rectal cancer
jRCT1022250050Phase 2Recruiting
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer. Primary endpoint: Clinical response rate. Started May 2026; status: recruiting.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCT1022250050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1022250050.